Related Experiment Videos
Angiostatin.
1Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden. yihai.cao@mtc.ki.se
Seminars in Thrombosis and Hemostasis
|March 23, 2004
Summary
Angiostatin, a fragment of plasminogen, inhibits tumor angiogenesis and growth. Its anti-angiogenic mechanism is being investigated for cancer therapy, with promising results in animal studies and ongoing clinical trials.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- The adult vascular system's quiescence results from an imbalance between angiogenesis inhibitors and factors.
- Tumors can produce endogenous angiogenesis inhibitors like angiostatin, which blocks tumor blood vessel formation.
- Angiostatin shows potent antitumor activity in preclinical models and is undergoing human clinical trials.
Purpose of the Study:
- To discuss the known aspects of angiostatin and its specific anti-angiogenic mechanisms.
- To provide insights into the therapeutic potential of angiostatin and related inhibitors.
Main Methods:
- Review of existing literature on angiostatin's origin and function.
- Analysis of angiostatin as a proteolytic fragment of plasminogen.
- Discussion of the role of proteolytic processing in angiogenesis regulation.
Main Results:
- Angiostatin is an internal fragment of plasminogen, not a novel protein.
- Specific kringle domains of plasminogen exhibit anti-angiogenic activity only when cleaved.
- Proteolytic processing is crucial for down-regulating angiogenesis.
Conclusions:
- Angiostatin's precise anti-angiogenic mechanism remains largely unknown.
- Understanding the mechanism is vital for predicting the success of clinical trials.
- Further research into angiostatin and its analogs could lead to novel cancer therapeutics.